Sobell JM, Elewski B, Banerjee S, Balagula E, Scharnitz T, Berger V, Hoyt K, Yamauchi P, Bettencourt M, Cameron MC, Lebwohl M. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI). J of Skin [Internet]. 2023 Nov. 13 [cited 2024 Jul. 3];7(6):s238. Available from: https://jofskin.org/33014/index.php/skin/article/view/2355